Hilf et al. [96] prepared two highly personalized vaccines and inoculated 15 patients with HLA-A*02:01- or HLA-A*24:02-positive glioblastoma, which elicited continuous T cell response and improved patients’ median total survival time to 29.0 months. This evidence concerns the gene HLA-A and glioblastoma.